Blood safety: Opportunities and challenges addressed through Critical Path research at FDA

New scientific discoveries and technologies create opportunities for medical and public health advancement through development of innovative products. However, novel products and technologies bring new challenges to regulation. FDA recently established a ‘Critical Path’ research initiative to modernize regulatory science concepts and tools to meet the challenges of the 21st century. Central to this initiative is the concept that regulatory science is distinct from the ‘discovery’ science that generates ideas for development of new drugs, biologics, or medical devices. In this article, the authors discuss the concepts of FDA ‘Critical Path’ research and review examples of such research performed in the Office of Blood Research and Review within the Center for Biologics Research and Evaluation at FDA to illustrate how the ‘Critical Path’ research is being used to address opportunities and challenges impacting blood and blood products.

Section editor:Janet Woodcock – Food and Drug Administration, Rockville, MD, USA